Introduction

The Cistor 10 mg (Cisplatin) Injection is a platinum-based chemotherapy agent designed for the first-line treatment of advanced lung cancer, head and neck cancer, ovarian carcinoma, bladder carcinoma, and testicular carcinoma. Manufactured by Eskayef Pharmaceuticals Ltd., a leader in high-quality oncology solutions, and supplied by Onco Solution, a global provider of life-saving cancer therapies, Cistor disrupts DNA replication in cancer cells while synergizing with other cytotoxic agents. Despite its narrow therapeutic margin, this injection remains a cornerstone in oncology due to its efficacy in aggressive cancer management.

Key Benefits

• Broad-Spectrum Efficacy: First-line therapy for lung, ovarian, bladder, testicular, and head/neck cancers.
• Synergistic Action: Enhances effectiveness of 5-fluorouracil, etoposide, and radiotherapy.
• Minimal Myelosuppression: Unlike many chemotherapies, Cistor causes limited bone marrow suppression at doses ≤100 mg.

Indications

The Cistor 10 mg (Cisplatin) Injection is indicated for:

• First-line treatment of advanced lung cancer, head and neck cancer, and metastatic ovarian carcinoma.
• Advanced bladder carcinoma and testicular carcinoma management.

Pharmacology

• Mechanism of Action: Cisplatin binds to DNA, causing cross-linking and disrupting replication during the S phase of the cell cycle. This leads to apoptosis (cell death) in rapidly dividing cancer cells.
• Synergy: Combines effectively with fluorouracil, cyclophosphamide, and radiotherapy for enhanced tumor suppression.

Dosage & Administration

Metastatic Ovarian Cancer

• Monotherapy: 100 mg/m² infused in 0.9% sodium chloride or glucose once every 4 weeks.
• Combination Therapy (with cyclophosphamide): 75–100 mg/m² on day 1 of a 4-week cycle.

Metastatic Testicular Tumors

• Dose: 20 mg/m² daily for 5 days per cycle.

Advanced Bladder Cancer

• Initial Dose: 50–70 mg/m² every 3–4 weeks (adjust based on prior radiation/chemotherapy exposure).
• Heavily Pre-Treated Patients: Start with 50 mg/m² every 4 weeks.

General Dosing Guidelines

• Adults & Children: 50–100 mg/m² as a single agent.
• Common Schedules:
  • 40–120 mg/m² IV on day 1 every 3 weeks.
  • 15–20 mg/m² IV on days 1–5 every 3–4 weeks.

Drug Interactions

• Synergistic Partners: 5-fluorouracil, etoposide, and radioprotectant WR 2721 (reduces toxicity).
• Avoid: Nephrotoxic agents (e.g., aminoglycosides) to prevent compounded kidney damage.

Contraindications

• Pre-existing renal impairment or myelosuppression.
• Hearing impairment or history of allergic reactions to platinum compounds.

Side Effects

Common Adverse Reactions:

• Severe Nausea/Vomiting: Requires antiemetic premedication.
• Nephrotoxicity: Monitor creatinine, BUN, and electrolytes.
• Ototoxicity: Tinnitus, hearing loss (especially in children).

Serious Risks:

• Bone Marrow Toxicity: Anemia, thrombocytopenia (rare).
• Neurotoxicity: Peripheral neuropathy, seizures, optic neuritis.
• Electrolyte Imbalance: Hypomagnesemia, hypocalcemia, hyperuricemia.

Pregnancy & Lactation

• Pregnancy Category D: Cistor may cause fetal harm. Use only in life-threatening scenarios where safer alternatives fail.
• Lactation: Discontinue breastfeeding due to potential infant toxicity.

Precautions & Warnings

1. Renal & Hepatic Monitoring:
   • Assess kidney/liver function before and during treatment.
   • Hydrate with 2 liters of IV fluid pre- and post-infusion to reduce nephrotoxicity.
2. Auditory & Neurological Checks:
   • Regular hearing tests and neurological exams.
3. Blood Counts: Monitor CBC to detect myelosuppression early.

Overdose Management

Acute overdose may cause kidney/liver failure, deafness, or fatal myelosuppression.
Treatment:

• Immediate hydration and forced diuresis.
• Supportive care for nausea, seizures, and electrolyte imbalances.

Reconstitution & Administration

• 10 mg Vial: Reconstitute with 10 ml sterile water for injection.
• 50 mg Vial: Reconstitute with 50 ml sterile water for injection.
• Infusion Protocol: Dilute reconstituted solution in 2 liters of 5% glucose or 0.9% saline. Administer IV over 6–8 hours.
• Post-Infusion Care: Maintain hydration and diuresis for 24 hours.

Storage Conditions

• Stability:
  • Unopened Vial: Store at 25°C; protect from light.
  • Reconstituted Solution: Stable for 28 days (protected from light) or 7 days under room light.

Why Choose Cistor 10 mg (Cisplatin) Injection?

• Proven Efficacy: Clinically validated for aggressive carcinomas with synergistic combination potential.
• Trusted Manufacturer: Produced by Eskayef Pharmaceuticals Ltd., a pioneer in Bangladesh’s pharmaceutical industry with 30+ years of expertise.
• Global Accessibility: Supplied by Onco Solution, ensuring affordable, reliable access to oncology treatments worldwide.

Technical Specifications

• Active Ingredient: Cisplatin (10 mg/vial).
• Packaging: Lyophilized powder in sterile vials with tamper-proof seals.
• Shelf Life: 24 months (unopened).

Commitment to Excellence

Eskayef Pharmaceuticals Ltd., part of the Transcom Group, combines innovation with stringent quality control to deliver life-saving therapies. Partnering with Onco Solution, they bridge global healthcare gaps, prioritizing affordability and accessibility without compromising efficacy.

Conclusion

The Cistor 10 mg (Cisplatin) Injection remains a critical tool in advanced cancer care, offering potent DNA-targeted action and synergistic benefits. By integrating this therapy, healthcare providers empower patients with a trusted option backed by Eskayef Pharmaceuticals Ltd. and Onco Solution – leaders in compassionate, evidence-based oncology.